Sign Out
CANCIDAS is indicated in adults and pediatric patients (12 months and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients.
Treatment of Invasive Candidiasis, including candidemia.
Treatment of Esophageal Candidiasis.
Treatment of Invasive aspergillosis in patients who are refractory to or intolerant of other therapies (i.e. amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
CANCIDAS has not been studied as initial therapy for invasive aspergillosis.
